A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis.
Carlo LazzaroCécile van SteenGiorgio GhirelliMatteo SacchiDario SistoMaurizio UvaLuigi VaranoLuigi AngelilloPublished in: Expert review of pharmacoeconomics & outcomes research (2022)
STN1013001 is potentially highly cost-effective and strongly dominant vs. Latanoprost for OAG/OHT+OSD patients from the INHS perspective. These findings should be re-assessed using the data from the ongoing Phase III trial (NCT04133311) comparing the efficacy and safety of STN1013001 vs. Latanoprost and with future real-world CUAs upon the availability of STN1013001 on the Italian market.
Keyphrases
- phase iii
- clinical trial
- open label
- end stage renal disease
- phase ii
- blood pressure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- study protocol
- placebo controlled
- double blind
- electronic health record
- big data
- randomized controlled trial
- patient reported outcomes
- artificial intelligence
- deep learning